Provided by Tiger Fintech (Singapore) Pte. Ltd.

Omeros

6.97
-0.1800-2.52%
Pre-market: 6.70-0.2700-3.87%06:15 EDT
Volume:697.13K
Turnover:5.04M
Market Cap:404.71M
PE:-2.59
High:7.67
Open:7.49
Low:6.94
Close:7.15
Loading ...

Omeros Is Maintained at Buy by D. Boral Capital

Dow Jones
·
11 Apr

Omeros Announces the Omeros Oncology Clinical Steering Committee for Aml to Help Guide Omeros’ Proprietary Oncotox-Aml Clinical Program

THOMSON REUTERS
·
10 Apr

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Business Wire
·
08 Apr

Omeros Corporation’s Earnings Call Highlights Progress and Challenges

TIPRANKS
·
02 Apr

Q4 2024 Omeros Corp Earnings Call

Thomson Reuters StreetEvents
·
01 Apr

Omeros Is Maintained at Buy by D. Boral Capital

Dow Jones
·
01 Apr

Omeros Corp (OMER) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ...

GuruFocus.com
·
01 Apr

Omeros Corporation Reports 2024 Financial Results

TIPRANKS
·
01 Apr

BRIEF-Omeros Corporation Q4 EPS USD -0.54 Versus. Ibes Estimate USD -0.78

Reuters
·
01 Apr

Omeros Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
01 Apr

Omeros: Q4 Earnings Snapshot

Associated Press Finance
·
01 Apr

Omeros Q4 2024 GAAP EPS $(0.63) Beats $(0.82) Estimate

Benzinga
·
01 Apr

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

THOMSON REUTERS
·
01 Apr

Omeros Corporation Q4 Net Income USD -31.4 Million

THOMSON REUTERS
·
01 Apr

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Business Wire
·
01 Apr

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
31 Mar

OMER S.p.a. Receives Buy Rating from Gianluca Bertuzzo FCA Due to Strong Performance and Promising Future Prospects

TIPRANKS
·
31 Mar

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Benzinga
·
28 Mar

Omeros Corp expected to post a loss of 78 cents a share - Earnings Preview

Reuters
·
28 Mar

Strong Buy Rating for Omeros Corporation Driven by Promising Narsoplimab Prospects and Strategic Advancements

TIPRANKS
·
27 Mar